

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




Fig. 1A




Fig. 1B




Fig. 1C






Fig. 1D

3133

SKBR3

MCF7



Key: Dotted line = preselection antibodies

Solid line = antibody pool after selection on breast cancer cells or individual Fab clone


2087 = breast cancer cell line

HMEC = Nonmalignant primary mammary epithelial cells

A549 = lung carcinoma cell line

HL60 = leukemia cell line

Fig. 2A



Key: Dotted line = preselection antibodies

Solid line = antibody pool after selection on breast cancer cells or individual Fab clone


2087 = breast cancer cell line

HMEC = Nonmalignant primary mammary epithelial cells

A549 = lung carcinoma cell line

HL60 = leukemia cell line


Fig. 2B




Key: Dotted line = preselection antibodies
 Solid line = antibody pool after selection on breast cancer cells or individual Fab clone
 MCF-7 = breast cancer cell line
 SKBR3 = breast cancer cell line
 3133 = breast cancer cell line
 3199 = breast cancer cell line
 2087 = breast cancer cell line
 HMEC = Nonmalignant primary mammary epithelial cells
 A549 = lung carcinoma cell line
 HL60 = leukemia cell line

Fig. 2C


2087



3199



14.6



14.6.11

Key: Dotted line = preselection antibodies

Solid line = antibody pool after selection on breast cancer cells or individual Fab clone

MCF-7 = breast cancer cell line

SKBR3 = breast cancer cell line

3133 = breast cancer cell line

3199 = breast cancer cell line


2087 = breast cancer cell line

HMEC = Nonmalignant primary mammary epithelial cells

A549 = lung carcinoma cell line

HL60 = leukemia cell line

Fig. 2D



Key: Dotted line = preselection antibodies

Solid line = antibody pool after selection on breast cancer cells or individual Fab clone

MCF-7 = breast cancer cell line


2087 = breast cancer cell line

HMEC = Nonmalignant primary mammary epithelial cells

A549 = lung carcinoma cell line

HL60 = leukemia cell line

Fig. 2E



Key: Dotted line = preselection antibodies

Solid line = antibody pool after selection on breast cancer cells or individual Fab clone

MCF-7 = breast cancer cell line


SKBR3 = breast cancer cell line

3133 = breast cancer cell line

3199 = breast cancer cell line

2087 = breast cancer cell line
 HMEC = Nonmalignant primary mammary epithelial cells
 A549 = lung carcinoma cell line
 HL60 = leukemia cell line

Fig. 2F



Key: Dotted line = preselection antibodies

Solid line = antibody pool after selection on breast cancer cells or individual Fab clone
 MCF-7 = breast cancer cell line
 2087 = breast cancer cell line
 HMEC = Nonmalignant primary mammary epithelial cells
 SKBR3 = breast cancer cell line
 A549 = lung carcinoma cell line
 3133 = breast cancer cell line
 3199 = leukemia cell line



Fig. 2G

HL60

A549

16.6

16.4.19



Key: Dotted line = preselection antibodies

Solid line = antibody pool after selection on breast cancer cells or individual Fab clone

2087 = breast cancer cell line

HMEC = Nonmalignant primary mammary epithelial cells

A549 = lung carcinoma cell line

HL60 = leukemia cell line

Fig. 2H




Fig. 3






Fig. 4





Tumor-infiltrating lymphocytes




Fig. 7A

sample	n	CD19+/IgG+	IgG/IgD+	CD19+/IgM+	IgM+/IgD+	CD19+/CD38+	CD19/CD40	CD19/CD95
TIL	6	95	40	30	66	30	95	11
tumor-draining lymph node	5	53	20	25	73	37	86	14
PBMC- breast cancer pt	5	41	34	47	90	46	65	45
PBMC - healthy donor	4	23	1	70	90	1	25	22

TIL B

marker	specificity
BCL2	antiapoptotic
CD10	pre-B
CD20	B
CD23	activation
CD27	memory
CD38	plasma cell
CD5	T, autoimmune B
HLADR	B / APC
Ki-67/CD20	B cell, proliferation

Fig. 7B




Fig. 8